Discover
DRTS
Alpha Tau Medical Ltd
13.32
1 x 13.27
4 x 13.99
bid
ask
-
0.15
1.11%
1 @ 04:00 PM
13.51 +0.19 (1.40%)
| Ytd | 169.09% | |
| 1y | 346.98% |
12.65
day range
13.80
2.87
52 week range
14.11
| Open | 13.73 | Prev Close | 13.47 | Low | 12.65 | High | 13.80 | Mkt Cap | 1.20B |
| Vol | 839.00K | Avg Vol | 916.88K | EPS | -0.67 | P/E | -19.88 | Forward P/E | -25.22 |
| Beta | 1.17 | Short Ratio | 1.98 | Inst. Own | 4.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 10.87 | 200-d Avg | 7.19 | 1yr Est | 14.20 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.14 | N/A | N/A | N/A |
| 2026-05-18 | 2026-03 | -0.13 | -0.26 | -0.13 | -100.00% |
| 2026-03-09 | 2025-12 | -0.13 | -0.14 | -0.01 | -7.69% |
| 2025-11-20 | 2025-09 | -0.12 | -0.14 | -0.02 | -16.67% |
| 2025-08-11 | 2025-06 | -0.12 | -0.13 | -0.01 | -8.33% |
| 2025-05-19 | 2025-03 | -0.14 | -0.12 | 0.02 | 14.29% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-04 | Barclays | Upgrade | Overweight | Overweight |
| 2026-06-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-28 | Barclays | Upgrade | Overweight | |
| 2026-05-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-19 | Piper Sandler | Upgrade | Neutral | Neutral |
Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-07-05 | LEVY RAPHI | Chief Financial Officer | 90.18K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | HighTower Advisors, LLC | 874.99K | 11.36M | 1.26% |
| 2026-03-30 | Aquamarine Financial (cayman) Ltd | 721.50K | 9.37M | 1.04% |
| 2026-06-29 | Apella Capital, LLC | 382.28K | 4.96M | 0.55% |
| 2026-03-30 | ARK Investment Management, LLC | 292.13K | 3.79M | 0.42% |
| 2026-03-30 | UBS Group AG | 286.69K | 3.72M | 0.41% |
| 2026-03-30 | Daytona Street Capital LLC | 146.11K | 1.90M | 0.21% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | ARK ETF Trust-ARK Israel Innovative Technology ETF | 277.09K | 3.60M | 0.40% |
| 2026-05-30 | RBB Fund, Inc.-Adara Smaller Companies Fund | 83.09K | 1.08M | 0.12% |
| 2026-05-30 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 53.40K | 693.12K | 0.08% |
| 2026-03-30 | Tidal Trust II-Even Herd Long Short ETF | 25.09K | 325.71K | 0.04% |
| 2026-04-29 | Dunham Funds-Dunham Small Cap Growth Fund | 27.11K | 351.90K | 0.04% |